Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ePsCas9
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Systemic
01
Overview
ePsCas9 is an engineered variant of the PsCas9 Type II-B family enzyme, developed as a highly efficient and precise CRISPR-Cas tool for therapeutic genome editing. It is designed for in vivo editing, delivered via mRNA formulated with lipid nanoparticles. This engineered enzyme demonstrates up to 20-fold increased activity across various targets while preserving safety advantages, including reduced off-targets and chromosomal translocations. It has shown high levels of editing in the Pcsk9 gene in mouse liver, indicating its potential for treating hypercholesterolemia.
- Brand names
- eSpOT-ON
- Other names
- engineered PsCas9
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on ePsCas9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ePsCas9.